Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Berruti

Showing results (51-60 of 150) with videos related to

Pageof 15
Sort By:
British Journal of Cancer|June 1, 1996
Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extensionA Berruti, A Piovesan, M Torta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanismE Bellini, A Pia, M P Brizzi, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 7, 2014
The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapyM Tampellini, A Ottone, I Alabiso, et al.
Endocrine|June 19, 2012
Management of adjuvant mitotane therapy following resection of adrenal cancerM Terzolo, A Ardito, B Zaggia, et al.
Anticancer Research|November 1, 1995
Biochemical picture of bone metabolism in breast cancer patients with bone metastasesA Berruti, M Torta, A Piovesan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2011
Characteristics of HIV care and treatment in PEPFAR-supported sitesScott J Filler, Andres A Berruti, Nick Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 23, 2009
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimenF Vignani, L Russo, M Tucci, et al.
Oncology Reports|June 16, 2000
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatmentA Berruti, L Dogliotti, G Osella, et al.
AIDS (London, England)|March 18, 2011
The cost of providing comprehensive HIV treatment in PEPFAR-supported programsNicolas A Menzies, Andres A Berruti, Richard Berzon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2019
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†S Filetti, C Durante, D Hartl, et al.
Pageof 15

Showing results (51-60 of 150) with videos related to

Sort By:
Pageof 15
British Journal of Cancer|June 1, 1996
Biochemical evaluation of bone turnover in cancer patients with bone metastases: relationship with radiograph appearances and disease extensionA Berruti, A Piovesan, M Torta, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanismE Bellini, A Pia, M P Brizzi, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|November 7, 2014
The prognostic role of baseline CEA and CA 19-9 values and their time-dependent variations in advanced colorectal cancer patients submitted to first-line therapyM Tampellini, A Ottone, I Alabiso, et al.
Endocrine|June 19, 2012
Management of adjuvant mitotane therapy following resection of adrenal cancerM Terzolo, A Ardito, B Zaggia, et al.
Anticancer Research|November 1, 1995
Biochemical picture of bone metabolism in breast cancer patients with bone metastasesA Berruti, M Torta, A Piovesan, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 25, 2011
Characteristics of HIV care and treatment in PEPFAR-supported sitesScott J Filler, Andres A Berruti, Nick Menzies, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 23, 2009
Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimenF Vignani, L Russo, M Tucci, et al.
Oncology Reports|June 16, 2000
Evaluation by dual energy X-ray absorptiometry of changed bone density in metastatic bone sites as a consequence of systemic treatmentA Berruti, L Dogliotti, G Osella, et al.
AIDS (London, England)|March 18, 2011
The cost of providing comprehensive HIV treatment in PEPFAR-supported programsNicolas A Menzies, Andres A Berruti, Richard Berzon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2019
Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†S Filetti, C Durante, D Hartl, et al.
Pageof 15